Balance Sheet

Cash Flow Statement

Amortization of Deferred Charges Amortization of Deferred Charges Amortizatization of Intangibles Amortizatization of Intangibles Asset Writedowns and Impairment Asset Writedowns and Impairment Beginning Cash Balance Beginning Cash Balance Capital Expenditures Capital Expenditures Cash from Financing Activities Cash from Financing Activities Cash from Investing Activities Cash from Investing Activities Cash from Operations Cash from Operations Change in Account Payables Change in Account Payables Change in Accured Expenses Change in Accured Expenses Change in Cash Change in Inventory Change in Inventory Change in Receivables Change in Receivables Depreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and Depletion Depreciation and Depletion Free Cash Flow Free Cash Flow Gains from Investment Securities Gains from Investment Securities Long-Term Debt Issuances Long-Term Debt Repayments Net Cash Flow Net Cash Flow Net Income Non-cash Items Non-cash Items Other financing activities Other financing activities Preferred Shares Issued Share-based Compensation Share-based Compensation Shares Issued Shares Repurchased Short-Term Debt issuances

Growth Metrics

Guided Therapeutics (GTHP) Dividends Paid - Common (2023 - 2024)

Guided Therapeutics' Dividends Paid - Common history spans 2 years, with the latest figure at $54824.0 for Q2 2024.

On a quarterly basis, Dividends Paid - Common changed N/A to $54824.0 in Q2 2024 year-over-year; TTM through Jun 2024 was $120120.0, a 83.96% increase, with the full-year FY2023 number at $65296.0, down 45.64% from a year prior.
Dividends Paid - Common hit $54824.0 in Q2 2024 for Guided Therapeutics, down from $65296.0 in the prior quarter.
Over the last five years, Dividends Paid - Common for GTHP hit a ceiling of $65296.0 in Q1 2023 and a floor of $54824.0 in Q2 2024.